Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOING Study: Regorafenib followed by nivolumab in hepatocellular carcinoma
2019-003108-10Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and nivolumab in hepatocellular carcinoma (HCC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Rate and type of AEs leading to treatment discontinuation. Started Nov 2019; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-003108-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003108-10.